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Introduction
Over 1.8 adults per 1000 develop acute venous thromboembolism (VTE) annually. 1 International guidelines recommend initial parenteral anticoagulation plus an oral vitamin-K antagonist (VKA) for >3 months. 1 While highly effective in reducing the risk of deep-vein thrombosis (DVT) and pulmonary embolism (PE) recurrence during therapy, there is considerable risk after treatment is stopped. One and five-year VTE recurrence risk is estimated to be 1-5% and 3-15% in patients with provoked VTE and 10% and 30% in those with unprovoked VTE. 1, 2 This ongoing risk raises the question as to the appropriate duration of anticoagulant therapy and whether extending treatment beyond the acute period would improve patient outcomes. Extended anticoagulant therapy also comes with risks, primarily that of bleeding that must be weighed against the possible benefits. Several randomized controlled trials (RCTs) have evaluated the practice of extended anticoagulation for the treatment of VTE. We aimed to systematically review the literature and to quantitatively evaluate the efficacy and safety of extended pharmacologic treatment of venous thromboembolism (VTE) through network meta-analysis (NMA).
Methods
We conducted a systematic literature search in MEDLINE (via Ovid), Embase and Cochrane Central databases from the earliest possible search date through September 2014.
The search strategy for MEDLINE is presented in Appendix A and a similar strategy was used for the other databases. A manual search was also performed using the references of clinical trials and review articles to identify additional relevant articles. Results of identified studies were supplemented when possible by contacting investigators for clarification or additional data. For
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
a study to be included in the analysis, it had to: 1) be an RCT evaluating patients who completed initial anticoagulant treatment for either a DVT, PE or both prior to randomization for the extension study; 2) compare extension of VTE treatment with an anticoagulant or antiplatelet to placebo or active control; and 3) report at least one outcome of interest [e.g., recurrent VTE (DVT and/or PE) or the composite of major bleeding or clinically relevant non-major bleeding (CRNMB)]. We also evaluated the individual components of these composite outcomes separately (DVT, nonfatal PE, fatal PE, major bleeding, CRNMB and all-cause mortality).
Two independent investigators separately reviewed all citations identified by the search for inclusion (title and abstract stage, full text stage) and abstracted data from included trials.
Disagreements were resolved through discussion. The following data were collected from each trial: author identification, year of publication, funding source, report of conflicts of interest, study design characteristics, study population (inclusion and exclusion criteria, geographic location, length of study, duration of patient follow-up), patient baseline characteristics, VTE treatment regimen (name, strength, frequency, dose, route of administration, duration of therapy, time in therapeutic range for VKA arms), and outcomes data (number of events, definitions, period of follow-up, and diagnostic tests for confirmation).
To assess the methodological quality of the included trials, the Cochrane Collaboration risk of bias tool was used. 3 This tool evaluates seven domains including sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and any other identifiable biases. Each individual domain is assessed as having low, high, or unclear risk of bias using the
guidance provided by the tool. The risk of bias was evaluated for each trial by two separate investigators and conflicts were resolved through discussion.
We first ran traditional pairwise meta-analysis on the primary outcomes of interest, when more than one trial comparing the same interventions was available. A random-effects model was used to calculate relative risks (RR) and pool baseline event rates, each with corresponding 95% confidence intervals (CIs). A p-value of <0.05 was considered statistically significant for all analyses. Statistical heterogeneity was addressed using the I 2 statistic, with values of 25%, 50% and 75% representing cut-off values for low, moderate and high likelihood of the presence of heterogeneity. 4 StatsDirect version 2.8.0 was used for these analyses.
In addition to traditional meta-analyses, NMA was performed. 5 NMA is a generalization of traditional pairwise meta-analysis that compares all pairs of treatments within a set of to NMA. 7 We implemented a random-effects model assuming common heterogeneity across all comparisons. In order to assess for the presence of whole network heterogeneity as well as inconsistency in our NMA, we utilized generalized Cochran Q statistics for multivariate metaanalysis as described by Krahn and colleagues. 8 We did not include two trials ,9,10 in the basecase analyses because the enrolled populations were unique in comparison to the remaining trials. AUREC-FVII trial enrolled patients with elevated factor 7 levels at baseline while Vitovec et al. enrolled patients with residual vein thrombosis at baseline. None of the other trials focused in on such a specific population which could have led to differing baseline risk of VTE.
Instead, we performed a sensitivity analysis on the primary outcomes by adding these two trials into the base-case analysis.
Results

Study selection and characteristics
The results of our literature search are presented in Figure 1 . After duplicates were removed, 928 citations were screened for inclusion. Of those, 890 and 27 citations were excluded at the abstract and full text level, respectively, leaving 11 citations reporting 12 unique trials [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] (Table 1) . Rivaroxaban 12 and idraparinux 16 were each evaluated in comparison to placebo in individual trials ( Figure 2 ). Two doses of apixaban (2.5mg and 5mg twice daily)
were compared to placebo in one trial 11 , and each dose was considered separately in our analysis (as a three arm trial). Dabigatran was compared to placebo in one trial and to warfarin in a second trial, both published within the same report. 13 VKAs were compared to either placebo or control (i.e., discontinuation of VKA therapy with no placebo administration) in five trials. 9, 10, [17] [18] [19] Finally, aspirin was compared to placebo in two trials. 14, 15 Six trials were judged to
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have low risk of bias in all domains evaluated (appendix Figure 1) . [11] [12] [13] [14] [15] Two trials had low risk of bias in all domains except the blinding of outcomes assessment in which the risk of bias was unclear. 16, 19 The remaining four trials, which all evaluated the active intervention of VKA, had unclear randomization procedures. 9, 10, 17, 18 Three of these trials had high risk of bias because the trials were not blinded to participants and personnel. 9, 17, 18 The 10 trials in our base-case analysis represent a total of 11,079 patients. [11] [12] [13] [14] [15] [16] [17] [18] [19] With the exception of one trial that enrolled exclusively patients with an index DVT, the index event was (0.03 to 1.08)]. We could not evaluate the composite bleeding outcome since this data was not reported in trials evaluating VKAs and we were unable to evaluate heterogeneity as there were
only two trials pooled for each direct pairwise comparison. The pooled proportion of patients with recurrent VTE amongst placebo or untreated controls was 11% (7% to 15%) with an I 2 value of 93.5% suggesting a high-likelihood of heterogeneity (Appendix Figure 2) . The pooled proportion of patients with major bleed and CRNMB amongst placebo or untreated controls was 1.9% (1.5% to 2.4%) with an I 2 value of 0% (Appendix Figure 3) .
Nine trials were included in the network to evaluate recurrent VTE and all active therapies were represented. [11] [12] [13] [14] [15] [16] [17] 19 According to results of the NMA, each individual active therapy decreased the risk of recurrent VTE significantly compared to placebo, with exception of aspirin which did not significantly impact this outcome ( Figure 3 ). Each individual active therapy, with exception of idraparinux, significantly reduced recurrent VTE risk in comparison to aspirin. There were no other significant differences in recurrent VTE risk when comparing one active therapy to another. There were no strong signals of whole network heterogeneity (p=0.112) or inconsistency (p=0.08).
Upon analysis of individual outcomes comparing each active therapy relative to placebo, all therapies decreased DVT risk with exception of aspirin and idraparinux and all therapies decreased non-fatal PE risk with exception of aspirin and apixaban 2.5mg (Table 2) . No significant findings were noted for the outcome of fatal PE and of the few therapies where PE could be evaluated, idraparinux significantly reduced risk versus placebo. Mortality risk was significantly decreased by apixaban 5mg compared to placebo [RR 0.29 (0.10 to 0.87)]. For each of these individual outcomes, there were no signs of network heterogeneity or inconsistency.
Seven trials were included in the network used to evaluate the composite bleeding outcome and all active therapies were represented. [11] [12] [13] [14] [15] [16] When compared to placebo, all active Lastly, we conducted an exploratory post-hoc analysis of the new oral anticoagulants for the two primary outcomes of interest ( Figure 4) . None of the anticoagulants differed in recurrent VTE risk in comparison to each other, as was seen in our base-case analysis. Apixaban 2.5mg reduced the risk of composite bleeding compared to dabigatran while both apixaban doses each decreased composite bleeding risk compared to rivaroxaban, again consistent with our base-case analysis. Of the active therapies which were significantly better than placebo in reducing VTE risk (apixaban 2.5mg, apixaban 5mg, dabigatran, rivaroxaban, idraparinux and VKAs), safety data suggests that dabigatran, rivaroxaban and VKAs each independently increased bleeding risk significantly compared with apixaban 2.5mg. There was no difference found when comparing the two studied apixaban doses. Post-hoc analysis of a model comprised of only the new oral anticoagulants supported this finding, suggesting that apixaban reduced the composite bleeding risk over dabigatran (apixaban 2.5mg dose) and rivaroxaban (both apixaban doses). An overall review of the efficacy and safety outcomes in this analysis suggests that apixaban may be the best choice for extended VTE treatment.
Discussion
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When evaluating individual components of the composite outcomes, efficacy was observed in the reduction of DVT and non-fatal PE risk. Limitations in the number of events and data reported for PE and fatal PE make interpretation of a lack of benefit in these outcomes less certain. Mortality was found to be significantly reduced with apixaban 5mg compared to
placebo while the 2.5mg dose of apixaban was trending in the same direction. However, given close to 200 statistical comparisons are presented, it is reasonable to expect 10 significant findings are in error. In addition, the number of deaths per treatment arm is small, lending more uncertainty to the results on mortality. Finally, most warfarin trials did not report CRNMB
which limited the power to analyze this outcome independently from major bleeding.
The results of this NMA reflect a patient population supported by guidelines for extended anticoagulation: unprovoked VTE with low to moderate bleeding risk. The trials included in our NMA evaluated either exclusively a population of patients with first unprovoked VTE or a mixed population of predominantly unprovoked cases. Patients with provoked VTE or recurrent VTE were not extensively represented. Pooling the proportion of patients with recurrent VTE in placebo and untreated controls suggested statistically significant heterogeneity in baseline risk for this outcome. Three trials appeared to have higher baseline VTE risk relative to the others, including both aspirin trials (WARFASA and ASPIRE) and the trial evaluating warfarin by Kearon et al. 14, 15, 19 These were three of the four trials that enrolled exclusively unprovoked VTE cases and therefore it is not surprising that the baseline risk was elevated in comparison to trials allowing enrolment of patients with provoked VTE events.
Another factor which may be contributing to the heterogeneity is the duration of treatment and follow-up, which was the longest for the aspirin trials at approximately 2 and 4 years.
Naturally with longer duration of follow-up, more events are likely to accumulate in comparison to the remaining trials which had a follow-up period of 1 year or less.
There are additional factors clinicians should consider when evaluating the applicability of these results. Gender was well balanced across trials. Although extremes of adult age were 20 Annual major bleeding rate was similar in the aspirin and placebo groups (0.5% vs. 0.4%, respectively). Findings from INSPIRE suggest that although less profound of an effect in reducing recurrent VTE compared to anticoagulants, aspirin remains an
option for further VTE protection in patients with unprovoked VTE after initial anticoagulant treatment. 20 Potential clinical scenarios include patients with bleeding risk that has increased to an unacceptable level or patients who may change their preference over time.
A prior NMA by Castellucci et. al. 21 concluded that extended VTE treatment with oral anticoagulants or antiplatelets reduced recurrent VTE risk compared to placebo or observation, although the reduction associated with aspirin did not reach statistical significance. Major bleeding was increased with either VKAs or dabigatran compared to placebo or observation.
Our literature base differed from this prior NMA in several ways although this did not seem to translate into differences in overall conclusions with exception of dabigatran's impact on major bleeding, which was not significantly increased compared to placebo in our analysis. Castellucci et al. included trials that evaluated ximelagatran and low-intensity warfarin which we did not include in our network based on contemporary practice options. We also required trials to perform randomization after completion of the acute treatment phase in order to be included in our NMA and we allowed inclusion of idraparinux.
Our analysis is unique from the prior NMA in that individual components of composite outcomes were also evaluated separately, and we evaluated the more contemporary bleeding outcome CRNMB. These analyses add to the clinical utility of the results since patients and clinicians may place differing values on the individual components of the composite outcomes and now can appreciate the relative contribution of each individual outcome in the overall reduction in VTE risk or increase in composite bleeding risk. In addition, we have a novel network focusing on newer anticoagulants, albeit a post-hoc analysis, that supported the findings from the primary network.
The results of this NMA should be considered in the context of its limitations. We were limited in our ability to evaluate statistical heterogeneity due to the small number of trials within each pair-wise comparison, or lack of greater than one trial. Similarly, our evaluation of consistency is limited since there were few instances where both direct and indirect data were available for a given comparison. Both evaluation of heterogeneity and consistency are subject to type I and type II error, and given the small size of the network, type II error cannot be ruled out. 22 An additional limitation due to the size of the network both in terms of overall number of trials and number of trials within each direct pairwise comparison is the relative width of confidence intervals accompanying our results. We evaluated individual components of the primary outcomes although for some outcomes results were also hindered by the small number of trials and events per pairwise comparison contributing to the imprecision observed.
Although our data supports extended anticoagulation at large, our analysis was not able to identify an optimal duration, since the trials used treatment periods ranging from 6 months to 4
years. Finally, to truly appreciate how differences in the baseline risk of VTE recurrence in the studied population impacts outcomes, an individual patient data meta-analysis would be ideal.
In summary, extended anticoagulation in VTE treatment is a reasonable strategy for long-term risk reduction of VTE recurrence. While most evaluated therapies were efficacious in reducing VTE recurrence relative to placebo, apixaban has an advantageous bleeding profile and may be preferentially selected for extended VTE treatment. 
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